このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Suzhou MedicalSystem Technology マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Weng Kang

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	1.7yrs
CEOの所有権	6.9%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	1.7yrs

経営陣の近況

Recent updates

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Subdued P/S Might Signal An Opportunity

Jun 26

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Shares Leap 30% Yet They're Still Not Telling The Full Story

Mar 08

CEO（最高経営責任者

Weng Kang (56 yo)

1.7yrs

在職期間

CN¥1,440,000

報酬

Mr. Weng Kang serves as General Manager and Executive Director of MedicalSystem (Beijing) Technology Co., Ltd., and MedicalSystem (Shanghai) Technology Co., Ltd. Mr. Kang served as the Chairman of the Boar...

取締役

名称	ポジション	在職期間	報酬	所有権
Weng Kang	Vice Chairman & Joint GM	1.7yrs	CN¥1.44m	6.88% CN¥ 201.5m
Jianghua Wang	Director & Deputy GM	no data	データなし	0.0077% CN¥ 224.7k
Biao Li	Supervisory Board Chairman	2.3yrs	データなし	0.13% CN¥ 3.7m
Ning Chen	Chairman	2.3yrs	データなし	データなし
Dong Li	Independent Director	1.7yrs	データなし	データなし
Min Chen	Independent Director	1.7yrs	データなし	データなし
Jiang Jun	Supervisor	1.7yrs	データなし	データなし

1.7yrs

平均在職期間

46yo

平均年齢

経験豊富なボード: 603990の取締役会は経験豊富ではない ( 1.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Suzhou MedicalSystem Technology マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Suzhou MedicalSystem Technology Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.26 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Suzhou MedicalSystem Technology Co., Ltd. to Report First Half, 2024 Results on Aug 10, 2024

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Subdued P/S Might Signal An Opportunity

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.038 loss in 1Q 2023)

Suzhou MedicalSystem Technology Co., Ltd., Annual General Meeting, May 20, 2024

Suzhou MedicalSystem Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Suzhou MedicalSystem Technology Co., Ltd.'s (SHSE:603990) Shares Leap 30% Yet They're Still Not Telling The Full Story

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) announces an Equity Buyback for CNY 30 million worth of its shares.

Suzhou MedicalSystem Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.075 loss per share (vs CN¥0.008 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.041 profit in 2Q 2022)

Suzhou MedicalSystem Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

First quarter 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 profit in 1Q 2022)

Third quarter 2022 earnings released: CN¥0.011 loss per share (vs CN¥0.012 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.054 (vs CN¥0.046 in 2Q 2021)

Investor sentiment deteriorated over the past week

Mianyang Haoxiang Holdings Co., Ltd agreed to acquire an unknown minority stake in Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) from Weng Kang, Yan Huanghong, Wang Jianhua and Fu Hong for approximately CNY 340 million.

Suzhou MedicalSystem Technology Co., Ltd. announced that it expects to receive CNY 238.92928 million in funding from Mianyang Haoxiang Holdings Co., Ltd

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 24% undervalued

Now 22% undervalued

Now 21% undervalued

Second quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.06 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.12 loss in 1Q 2020)

New 90-day low: CN¥29.95

New 90-day low: CN¥30.70

New 90-day low: CN¥31.00

New 90-day low: CN¥37.65

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed an agreement to acquire remaining 49% stake in Haikou Mary Hospital Co., Ltd.

Third quarter earnings released

Suzhou MedicalSystem Technology Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥41.30

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed an equity acquisition intention agreement to acquire 51% stake in Heilongjiang Tianyuan Obstetrics and Gynecology Hospital Co., Ltd. from Tibet Daming Investment Management Co., Ltd. and Xue Weiwei for approximately CNY 170 million.

Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) signed a letter of intent to acquire 51% stake in a Hospital located in Heilongjiang for approximately CNY 170 million.

Earnings released

Zhongruo (Suzhou) Asset Management Co., Ltd. completed the acquisition of 5.34% stake in Suzhou MedicalSystem Technology Co., Ltd. (SHSE:603990) from Hangzhou Anshi Investment Management Partnership Enterprise (Limited Partnership).

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04